The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia

An Open Randomized Pilot Trial on the Differential Effects of Aripiprazole versus Risperidone on Anhedonia and Subjective Well-Being

“…An increased dopamine release is suggested to improve negative symptoms. However, in line with earlier studies, this study did not show a superior effect of aripiprazole on negative symptoms [26][27][28]. It might be that negative symptoms are a too broadly defined concept, and Table 1 Demographical data of the aripiprazole and risperidone groups, which shoviied no significant differences.…”

“…Thus given its putative working mechanism, aripiprazole may stabilize dopaminergic transmission in different brain regions [12,13,25] and in this way improve negative symptoms. Previous studies showed that aripiprazole has a beneficial effect on negative symptoms [26][27][28], cognitive functioning [28,29] and quality of life [27,30], but that these effects are not superior to those of other atypical antipsychotics [26,27,28]. These studies addressed a broad domain of symptoms while the effects of aripiprazole may be more specific.…”

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment

“…In addition, four other meta-analyses also stood out as very well-performed studies [33,34,102,161]. Most of the high-risk scores in this category were generated by a subset of nine studies that did not properly define the study inclusion criteria, the search strategy, and how the specific studies were selected [24,43,51,92,94,116,125,138,155]. Many of the unclear risk score results also came from these studies and resulted from not describing how the data were collected, for not assessing the quality/ bias of the included studies, and/or for not performing sensitivity analyses.…”

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study

“…The mechanism of action of aripiprazole is not yet known, but evidence suggests that its efficacy in the treatment of the positive and negative symptoms of schizophrenia and its lower propensity for extra-pyramidal symptoms (EPS) may be attributable to aripiprazole's partial agonist activity at dopamine D2 receptors. In general, while aripiprazole was associated with improvements in a broad range of symptom domains in the short-term treatment of schizophrenia and schizoaffective disorder [14], it was associated with a placebo-level incidence of EPS and EPS-related adverse events [15]. Flupenthixol is a non-sedating antipsychotic drug of the thioxanthene group.…”